II. Comments

Interested persons may submit either electronic comments regarding the CPG to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http://www.regulations.gov.

III. Electronic Access

Persons with access to the Internet may obtain the CPG at either http://www.fda.gov/ora/compliance_ref/cpg/default.htm or at http://www.regulations.gov. Use the FDA Web site listed in the previous sentence to find the most current version of the CPG.

Dated: July 10, 2013.

Leslie Kux,
Assistant Commissioner for Policy.

[FR Doc. 2013–16975 Filed: 7–15–13; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expedient commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT:

 Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301–496–7057; fax: 301–402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of patent applications.

Islet Beta Cell Only M3 Muscarinic Acetylcholine Receptor Knockout Mouse

Description of Technology:

Researchers at NIH have developed islet beta cell M3 muscarinic acetylcholine receptor knockout mouse. The mice were generated by crossing floxed mouse M3 muscarinic acetylcholine receptor mice with mice in which Cre recombinase was controlled by the beta-cell specific rat insulin promoter (RIP-Cre mice).

Potential Commercial Applications:


Development Stage: In vivo data available

Inventor: Jürgen Wess, Ph.D. (NIDDK)


Licensing Contact: Jaime M. Greene, M.S.; 301–435–5559; greenejaime@mail.nih.gov.

Transgenic Mice Overexpressing Islet Beta Cell M3 Muscarinic Acetylcholine Receptors

Description of Technology:

Researchers at NIH have generated transgenic mice in which the M3 muscarinic receptor is overexpressed in pancreatic beta cells. This was done by placing the receptor gene under the control of the 650 bp rat insulin promoter II (RIP II). The resulting mice show a pronounced increase in glucose tolerance and enhanced plasma insulin levels. Strikingly, these mutant mice were resistant to diet-induced glucose intolerance and hyperglycemia.

Potential Commercial Applications: Diabetes research, especially type II Diabetes.

Competitive Advantages: These transgenic mice overexpress the M3 muscarinic acetylcholine receptor only in pancreatic beta cells but notably are resistant to diet-induced glucose intolerance and hyperglycemia.

Development Stage: In vivo data available

Inventor: Jürgen Wess, Ph.D. (NIDDK).


Licensing Contact: Jaime M. Greene, M.S.; 301–435–5559; greenejaime@mail.nih.gov.

An Improved System for Production of Recombinant Baculovirus

Description of Technology:

Baculoviruses have been used for decades to produce proteins in insect cell hosts. Current systems for generating recombinant baculovirus have several shortcomings which prevent their easy use in high-throughput applications. The present
invention discloses an improved system to quickly and efficiently generate recombinant baculoviruses which produce recombinant proteins. In the new system, the baculovirus transfer vector, transposition helper plasmid and E. coli strain carrying the bacmid DNA were modified to eliminate the need for screening positive clones and improve the efficiency of baculovirus production. Taken together, these improvements permit facile high-throughput recombinant baculovirus production at reduced cost and improved speed over the currently available systems.

**Potential Commercial Applications:**
- High-throughput protein production
- Generation of virus-like particles in insect cells

**Competitive Advantages:**
- Elimination of background plasmid DNA during recombinant baculovirus production
- Elimination of nonproductive transposition events leading to false positives
- Lower cost production of baculovirus
- Increased speed of baculovirus production (allowing high-throughput production with limited screening)
- Higher efficiency cloning of baculovirus constructs

**Development Stage:**
- Prototype
- Pilot
- In vitro data available

**Inventor:** Dominic Esposito (NCI).


**Licensing Contact:** Susan Ano, Ph.D.; anos@mail.nih.gov.

Dated: July 9, 2013.

**Richard U. Rodriguez,**
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2013–16940 Filed 7–15–13; 8:45 am]

BILLING CODE 4140–01–P

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Center for Complementary & Alternative Medicine; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Center for Complementary and Alternative Medicine Special Emphasis Panel RFA–AT–11–011: Mechanistic Research on CAM Natural Products (R01).

**Date:** September 13, 2013.
**Time:** 7:00 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20892.

**Contact Person:** Martina Schmidt, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Complementary & Alternative Medicine, NIH, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892, 301–594–3456, schmidtma@mail.nih.gov.

[Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Alternative Medicine, National Institutes of Health, HHS]

Dated: July 10, 2013.

**Michelle Trout,**
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–16939 Filed 7–15–13; 8:45 am]

BILLING CODE 4140–01–P

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Neurological Disorders and Stroke Special Emphasis Panel; EUREKA.

**Date:** August 14, 2013.
**Time:** 8:00 a.m. to 6:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Melrose Hotel, 2430 Pennsylvania Ave. NW., Washington, DC 20037.

**Contact Person:** Natalia Strunnikova, Ph.D., Scientific Review Officer, Scientific Review Special Emphasis Panel; Member Conflict: Risk, Prevention and Health Behavior.

Dated: August 14, 2013.